The team at Harvard Medical School’s Laboratory of Systems Pharmacology are focused on cancer and on analyzing the ways cancer drugs affect the whole body. They aim to reinvent the drug development process through this systems approach, by going much deeper than would scientists supervising a typical clinical trial and by establishing a new model of collaboration. Peter Sorger, head of the Program in Therapeutic Science and professor of systems pharmacology, and Jerry Lin, research fellow in systems biology, are quoted.
